HUSH Restriction in HIV Infected Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04172480 |
Recruitment Status :
Recruiting
First Posted : November 21, 2019
Last Update Posted : December 20, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
HIV Infections | Other: Blood sampling |
Study Type : | Observational |
Estimated Enrollment : | 50 participants |
Observational Model: | Case-Only |
Time Perspective: | Prospective |
Official Title: | HUSH Restriction in HIV Infected Patients |
Actual Study Start Date : | October 1, 2019 |
Estimated Primary Completion Date : | September 30, 2023 |
Estimated Study Completion Date : | September 30, 2023 |
Group/Cohort | Intervention/treatment |
---|---|
acute HIV1 infection
Patient infected by HIV1, prior treatment initiation
|
Other: Blood sampling
Peripheral blood sampling on EDTA |
chronic HIV1 infection
Patient infected by HIV1, untreated or without treatment since at least 3 months
|
Other: Blood sampling
Peripheral blood sampling on EDTA |
HIV2 infection
Patient infected by HIV2, untreated or without treatment since at least 3 months
|
Other: Blood sampling
Peripheral blood sampling on EDTA |
- Viremia [ Time Frame: Baseline ]Intracellular HIV RNA load expressed in number of copies / ml
- Total HIV DNA and integrated HIV DNA [ Time Frame: Baseline ]Quantification by qPCR
- Hush activity [ Time Frame: Baseline ]Transcription rate of cellular genes targeted by HUSH by qRT-PCR
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 15 Years to 80 Years (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria for group 1:
- Symptomatic or asymptomatic acute HIV1 infection
- Age above 15 years old
- No ARV treatment prior inclusion (excepted as prophylaxis pre or post exposure)
Inclusion Criteria for group 2:
- Chronic HIV1 infection
- Age above 18 years old
- No ARV treatment since at least 3 month (regardless the reason)
Inclusion Criteria for group 3:
- HIV2 Infection
- Age above 18 years old
- No ARV treatment since at least 3 month (regardless the reason)
Exclusion Criteria for all groups:
- HIV1 and HIV2 co-infection
- Evolutive intercurrent pathology, in particular active co-infection (i.e. HBV, HCV, tuberculosis, HTLV1)
- Life-threatening pathology

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04172480
France | |
Hôpital Bicêtre | Not yet recruiting |
Le Kremlin-Bicêtre, France, 94270 | |
Contact: Antoine CHERET, MD 1 45 21 25 77 ext 33 antoine.cheret@aphp.fr | |
Hôtel-Dieu | Recruiting |
Paris, France, 75004 | |
Contact: Jean-Paul VIARD, Pr 1 42 34 88 36 ext 33 jean-paul.viard@aphp.fr | |
Hôpital Necker | Not yet recruiting |
Paris, France, 75015 | |
Contact: Claudine DUVIVIER, MD 1 44 38 17 42 ext 33 duvivier@nck.aphp.fr |
Responsible Party: | ANRS, Emerging Infectious Diseases |
ClinicalTrials.gov Identifier: | NCT04172480 |
Other Study ID Numbers: |
ANRS RF 004 |
First Posted: | November 21, 2019 Key Record Dates |
Last Update Posted: | December 20, 2021 |
Last Verified: | December 2021 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
HIV Infections Blood-Borne Infections Communicable Diseases Infections Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases |
Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Immunologic Deficiency Syndromes Immune System Diseases |